One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2023.06.010
Volume 84, Issue 2, August 2023, Pages e35-e45
Guidelines for Reporting Observational Research in Urology: The Importance of Clear Reference to Causality
Andrew J. Vickers a,*, Melissa Assel a , Rodney L. Dunn b , Emily C. Zabor c , Michael W. Kattan c , Maarten van Smeden d , Darren Dahly
doi : 10.1016/j.eururo.2023.04.027
Volume 84, Issue 2, August 2023, Pages 147-151
Pregnancy and Urology Residency: Towards Equity-centred Practice
Laura S. Mertens a , Ge´raldine Pignot b , Luca Afferi c , Juan Luis Va´squez d , Carmen Mir e , Benjamin Pradere
doi : 10.1016/j.eururo.2023.05.020
Volume 84, Issue 2, August 2023, Pages 152-153
Moving the Needle: Antibiotic Prophylaxis Is No Longer Required in the Era of Transperineal Prostate Biopsy
Peter Ka-Fung Chiu a,*, Veeru Kasivisvanathan b,c , Giorgio Gandaglia d,e , on behalf of the European Association of Urology Young Academic Urologists Prostate Cancer Working Party
doi : 10.1016/j.eururo.2023.04.007
Volume 84, Issue 2, August 2023, Pages 154-155
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
Oliver Sartor a,*, Theodore G. Karrison b , Howard M. Sandler c , Leonard G. Gomella d , Mahul B. Amin c , James Purdy e , Jeff M. Michalski f , Mark G. Garzotto g , Nadeem Pervez h , Alexander G. Balogh i , George B. Rodrigues j , Luis Souhami k , M. Neil Reaume l , Scott G. Williams m , Raquibul Hannan n , Christopher U. Jones o , Eric M. Horwitz p , Joseph P. Rodgers b , Felix Y. Feng q , Seth A. Rosenthal
doi : 10.1016/j.eururo.2023.04.024
Volume 84, Issue 2, August 2023, Pages 156-163
Adjuvant Docetaxel in Nonmetastatic Prostate Cancer: The King Is Dead, Long Live the King!
Thomas Van den Broeck a,b,*, Steven Joniau a,c , Wouter Everaerts
doi : 10.1016/j.eururo.2023.05.033
Volume 84, Issue 2, August 2023, Pages 164-165
Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma
Brittney H. Cotta a , Toni K. Choueiri b , Marcin Cieslik c,d , Pooja Ghatalia e , Rohit Mehra c,d,f , Todd M. Morgan a,f , Ganesh S. Palapattu a,f , Brian Shuch g , Ulka Vaishampayan f,h , Eliezer Van Allen b , A. Ari Hakimi i,1, Simpa S. Salami
Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors
Ibrahim Jubber a,b,*, Sean Ong c,d , Laura Bukavina e , Peter C. Black f , Eva Compe´rat g , Ashish M. Kamat h , Lambertus Kiemeney i , Nathan Lawrentschuk c,d,j , Seth P. Lerner k , Joshua J. Meeks l , Holger Moch m , Andrea Necchi n , Valeria Panebianco o , Srikala S. Sridhar p , Ariana Znaor q , James W.F. Catto a,b , Marcus G. Cumberbatch
doi : 10.1016/j.eururo.2023.03.029
Volume 84, Issue 2, August 2023, Pages 176-190
2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
doi : 10.1016/j.eururo.2023.04.021
Volume 84, Issue 2, August 2023, Pages 191-206
Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms
Stavros Gravas a , Mauro Gacci b,c , Christian Gratzke d , Thomas R.W. Herrmann e , Markos Karavitakis f , Iason Kyriazis g , Sachin Malde h , Charalampos Mamoulakis f , Malte Rieken i , Vasileios I. Sakalis j,*, Natasha Schouten k , Mark J. Speakman l , Kari A.O. Tikkinen m,n , Jean-Nicolas Cornu
doi : 10.1016/j.eururo.2023.04.008
Volume 84, Issue 2, August 2023, Pages 207-222
Simplifying Retroperitoneal Robotic Single-port Surgery: Novel Supine Anterior Retroperitoneal Access
Antony A. Pellegrino a,b,c,*, Grace Chen c , Luca Morgantini c , Ruben Sauer Calvo c , Simone Crivellaro
doi : 10.1016/j.eururo.2023.05.006
Volume 84, Issue 2, August 2023, Pages 223-228
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
Andrew J. Armstrong a,*, Taro Iguchi b , Arun A. Azad c,y, Arnauld Villers d , Boris Alekseev e , Daniel P. Petrylak f , Russell Z. Szmulewitz g , Antonio Alcaraz h , Neal D. Shore i , Jeffrey Holzbeierlein j , Francisco Gomez-Veiga k,Ã , Brad Rosbrook l , Fabian Zohren l , Gabriel P. Haas m , Georgia Gourgiotti n , Nader El-Chaar m , Arnulf Stenzl
doi : 10.1016/j.eururo.2023.04.002
Volume 84, Issue 2, August 2023, Pages 229-241
Re: Hydrochlorothiazide and Prevention of Kidney-stone Recurrence
Julian Veser
doi : 10.1016/j.eururo.2023.03.022
Volume 84, Issue 2, August 2023, Pages 242-243
Re: Inhibition of Sodium-Glucose Cotransporter 2 Suppresses Renal Stone Formation
Palle Osther
Re: Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium
Jianliang Liu a,b Daniel Moon c Nathan Lawrentschuk
doi : 10.1016/j.eururo.2023.03.034
Volume 84, Issue 2, August 2023, Pages 244-245
Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Abhishek D. Sharma a Jose F. Lopez a,b Aaron Leiblich a Tom A. Leslie a,b Alastair D. Lamb
doi : 10.1016/j.eururo.2023.03.033
Volume 84, Issue 2, August 2023, Pages 245-246
Re: Pain and Health-related Quality of Life with Olaparib Versus Physician’s Choice of Next-generation Hormonal Drug in Patients with Metastatic Castration-resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An Open-label, Randomised, Phase 3 Trial
Sola Adeleke a,b,* Aruni Ghose c,d Stergios Boussios
doi : 10.1016/j.eururo.2023.03.023
Volume 84, Issue 2, August 2023, Pages 246-247
Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries
Lydia E. Makaroff a,b , Alex Filicevas a , Shannon Boldon a , Patrick Hensley c,d , Peter C. Black d,e,f,g,h , Stephanie Chisolm a,i , Stephanie Demkiw a,j,k , Mario I. Ferna´ndez d,l , Mikio Sugimoto m , Bente Thoft Jensen n , Wim P.J. Witjes o , Ken Bagshaw a,h , Lori Cirefice-Funk a,p , Allen Knight a,q , Ashish M. Kamat
doi : 10.1016/j.eururo.2023.04.034
Volume 84, Issue 2, August 2023, Pages 248-251
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. 2023;83:561–70
Zhipeng Mai Weigang Yan Zhien Zhou
doi : 10.1016/j.eururo.2023.03.043
Volume 84, Issue 2, August 2023, Pages e46-e47
Reply to Zhipeng Mai, Weigang Yan, and Zhien Zhou’s Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70
Gabriela Ilie a,b,c,* Robert D.H. Rutledge
doi : 10.1016/j.eururo.2023.05.015
Volume 84, Issue 2, August 2023, Pages e48-e49
Re: Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020
Mattias H?glund *, on behalf of the members of the Lund Bladder Cancer Group
doi : 10.1016/j.eururo.2023.04.039
Volume 84, Issue 2, August 2023, Page e50
Reply to Mattias Höglund’s Letter to the Editor re: Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020
Niklas Klümper a,b,c,d,* Alexander Cox a,b Markus Eckstein
doi : 10.1016/j.eururo.2023.05.016
Volume 84, Issue 2, August 2023, Pages e51-e52
Re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43–6
Alireza Ghoreifi Hooman Djaladat
doi : 10.1016/j.eururo.2023.03.042
Volume 84, Issue 2, August 2023, Pages e53-e54
Reply to Alireza Ghoreifi and Hooman Djaladat’s Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43–6
Daniel D. Shapiro a,* Jose A. Karam b Viraj A. Master c Logan W. Zemp d Wade J. Sexton d Surena F. Matin b Philippe E. Spiess d E. Jason Abel
doi : 10.1016/j.eururo.2023.04.023
Volume 84, Issue 2, August 2023, Pages e55-e56
